Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells

Prostate Cancer and Prostatic Diseases

Volumn 4, Issue 2, 2001, Pages 81-91

  Liu, Y Q ^a   Kyle, E ^b   Patel, S ^b   Housseau, F ^b   Hakim, F ^b   Lieberman, R ^b   Pins, M ^a   Blagosklonny, M V ^b   Bergan, R C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cell growth; Chemoprevention; Preclinical models; Prostate cancer; Treatment

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; DOXORUBICIN; ESTER DERIVATIVE; GENISTEIN; PERILLIC ACID; PERILLYL ALCOHOL; PERILLYL ALCOHOL METHYLESTER; TAMOXIFEN; TOREMIFENE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VINBLASTINE;

ADVANCED CANCER; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER STAGING; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOLOGY; DRUG RESPONSE; DRUG SCREENING; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MALE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; VALIDATION PROCESS;

EID: 0034947013     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500506     Document Type: Article

References (55)

1. Cancer of the prostate
2. Cancer Statistics, 2000
3. Management of hormone refractory prostate cancer: Current standards and future prospects
4. Molecular biology of prostate carcinogenesis
5. Molecular biology of prostate development and prostate cancer
6. Clinical evidence for and implications of the multistep development of prostate cancer
7. Prostatic intraepithelial neoplasia is a risk factor for cancer
8. The multistep nature of cancer
9. Molecular themes in oncogenesis
10. Preclinical models of prostate cancer
11. Progress in cancer chemoprevention
12. Metastatic behavior of human tumor cell lines grown in the nude mouse
13. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity
14. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens
15. Electroporation of synthetic oligodeoxynucleotides: A novel technique for ex vivo bone marrow purging
16. Growth inhibition of chronic myelogenous leukemia cells by ODN-1, an aptameric inhibitor of p210bcr-abl tyrosine kinase activity
17. Growth inhibition of prostate cancer cells by tamoxifen is associated with protein kinase C inhibition and induction of p21 waf1/cip1
18. Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin
19. Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy
20. Inhibition of proteintyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides
21. Aptameric inhibition of p210bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure
22. Amplification of human beta-actin gene by the reverse transcriptase-polymerase chain reaction: Implications for assessment of RNA from formalin-fixed, paraffin-embedded material
23. Detection of prostatic cells in peripheral blood: Correlation with serum concentrations of prostate-specific antigen
24. DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction
25. Molecular and cell biology of TGF-beta
26. Some recent advances in the chemistry and biology of transforming growth factor-beta
27. Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications. Cell markers and immortalized nontumorigenic cell lines
28. Culture of human prostatic epithelial cells
29. Prostate specific antigen and androgen receptor induction and characterization of an immortalized adult human prostatic epithelial cell line
30. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18
31. Immortalization of human adult normal prostatic epithelial cells by liposomes containing large T-SV40 gene
32. Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA
33. Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice
34. Establishment and characterization of a human prostatic carcinoma cell line (PC-3)
35. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization
36. Expression of focal adhesion kinase in prostate cancer
37. Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications. Oncogenes, suppressor genes, and applications
38. Loss of expression of transforming growth factor β type I and type II receptors correlates with tumor grade in human prostate cancer tissues
39. Transforming growth factor betal stimulates contrasting responses in metastatic vs primary mouse prostate cancer-derived cell lines in vitro
40. Differential effects of transforming growth factor beta on human prostate cancer cells in vitro
41. Expression of transforming growth factor-beta 1 in prostate cancer
42. Transforming growth factor-beta 1: Comparative immunohistochemical localization in human primary and metastatic prostate cancer
43. Incidence of apoptosis and cell proliferation in prostate cancer: Relationship with TGF-beta 1 and bcl-2 expressing
44. Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate
45. A retrospective and prospective overview of prostate-specific antigen
46. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma
47. Molecular biology of cancer: The cell cycle
48. Molecular biology of cancer: Invasion and metastasis
49. Plant alkaloids
50. Anthracyclines
51. Clinical development plan: 1-perillyl alcohol
52. Topoisomerase interactive agents
53. Antimicrotubule agents
54. Cancer chemoprevention agent development strategies for genistein
55. A phase II study of high dose tamoxifen in patients with hormone refractory prostate cancer